Neurological
Refine Search
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Pharmaceutical
Some 55 attorneys general (AGs), representing all eligible states and US territories, have agreed to sign on to a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family. 17 June 2025
Pharmaceutical
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
Biotechnology
Swiss pharma giant Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease (PD). 16 June 2025
Biotechnology
Notable research news last week included US biopharma Avidity Biosciences announcing a positive update on its muscular dystrophy candidate delpacibart braxlosiran (del-brax), and Dutch firm NewAmsterdam released new Phase III on its investigational Alzheimer’s drug obicetrapib. US Health Secretary Robert F Kennedy Jr announced he has dismissed an independent panel of vaccine experts in order to restore trust in vaccines. Also of note, Merck & Co gained US food and Drug Administration (FDA) for its Enflonsia for the prevention of respiratory syncytial virus (RSV). 15 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Japanese biotech Nxera Pharma has received a $15 million payment from Neurocrine Biosciences after the first patient was dosed in a Phase III study of NBI-1117568, a potential new treatment for schizophrenia. 3 June 2025
Biotechnology
Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). 2 June 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Pharmaceutical
US biotech GRIN Therapeutics has secured $140 million in Series D funding and signed a licensing deal with Italy's Angelini Pharma that could bring in more than $500 million in future payments tied to its lead investigational therapy, radiprodil. 28 May 2025
Pharmaceutical
New York-based neurosciences company Gilgamesh Pharmaceuticals yesterday announced Phase IIa results for GM-2505, a novel, rapid-acting 5-HT2A receptor agonist and 5-HT releaser in development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). 28 May 2025
Pharmaceutical
Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for immunology, inflammation, and neurology disorders, has appointed Mona Kotecha as chief medical officer (CMO). 19 February 2025
Biotechnology
Germany-based Bayer’s wholly-owned gene therapy company AskBio today announced that its investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA). 19 February 2025
Pharmaceutical
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, has announced the appointments of Lahar Mehta as chief medical officer and Scott Greenberg as chief business officer. 18 February 2025
Pharmaceutical
US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. 18 February 2025
Pharmaceutical
Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop and commercialize a treatment for Dravet Syndrome, a severe form of epilepsy that starts in childhood. 18 February 2025
Pharmaceutical
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a compound annual growth rate (CAGR) of 31.3% (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027. 18 February 2025
Biotechnology
Swiss biotech Oculis Holding yesterday announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses. 14 February 2025
Pharmaceutical
Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, has announced its emergence and the closing of an oversubscribed $93.5 million Series A financing. 13 February 2025
Pharmaceutical
Danish biopharma giant Novo Nordisk is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage study shows its potential in treating alcohol-use disorder (AUD). 13 February 2025
Biotechnology
Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product launches. 12 February 2025
Biotechnology
US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 12 February 2025
Pharmaceutical
Vertex Pharmaceuticals expects another year of rapid growth in 2025, after achieving this in the fourth quarter and throughout 2024 as a whole. 11 February 2025
Pharmaceutical
France-based biopharma company Medincell this morning revealed it is to receive a $5 million development milestone from Israel’s Teva Pharmaceutical Industries as the SOLARIS study completed. 10 February 2025
Pharmaceutical
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders. 7 February 2025
Pharmaceutical
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo (apomorphine hydrochloride). 5 February 2025
Pharmaceutical
Danish CNS specialist Lundbeck today released financial results for fourth-quarter and full-year 2024. 5 February 2025
Biotechnology
Affinia Therapeutics, a US biotech with a pipeline of rationally designed adeno-associated virus (AAV) gene therapies for cardiovascular and neurological diseases, has announced the appointment of Hideo Makimura as its chief medical officer (CMO). 5 February 2025
Pharmaceutical
Dublin-headquartered GH Research was trading around 80% higher early on Monday. 3 February 2025
Pharmaceutical
The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% from $3.4 billion in 2023 to $7.9 billion in 2033. 3 February 2025
Pharmaceutical
Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing results from a Phase II trial of patients with untreated Parkinson's disease. 31 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze